YKL-1-116
YKL-1-116 is a selective and covalent inhibitor of Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 toward both Cdk7WT and Cdk7as, although Cdk7as is relatively resistant to this compound as well[1].
Product Specifications
CAS Number
1957202-71-9
Product Name Alternative
Ro 40-7591 D7
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ykl-1-116.html
Purity
98.67
Solubility
10 mM in DMSO
Smiles
CC(C)(N(C1)C(N[C@@H](C2=CC=CC=C2)CN(C)C)=O)C3=C1C(NC4=CC(NC(C5=CC=C(C=C5)NC(C=C)=O)=O)=CC=C4)=NN3
Molecular Formula
C34H38N8O3
Molecular Weight
606.72
References & Citations
[1]Kalan S, et al. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep. 2017 Oct 10;21 (2) :467-481.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK7
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
2-Phenoxyethyl-2,2’-thenylaminoethane, Hydrochloride
MAD2L1 binding protein (MAD2L1BP) (N-term) Rabbit Polyclonal Antibody
